Literature DB >> 18397173

Recent progress in the discovery of novel glucocorticoid receptor modulators.

Hidenori Takahashi1, Hossein Razavi, David Thomson.   

Abstract

Glucocorticoids have been used in modern clinical practice for over fifty years. Although they have demonstrated potent anti-inflammatory and immunosuppressive activities, their association with debilitating and life-threatening side effects has been a major drawback. Recent insights into glucocorticoid biology have lent support to the hypothesis that the glucocorticoid anti-inflammatory activities could be dissociated from their adverse side effects. Inspired by these biological findings, the search for dissociated glucocorticoid receptor agonists has intensified. Antag-onists of the glucocorticoid receptor that offer therapeutic benefits for the treatment of diseases such as diabetes have also been pursued. These efforts have been partly focused on the development of tissue, especially liver, selective glucocor-ticoid receptor antagonists, which are thought to have improved safety profiles. This review offers a summary of the research and development activities in this field and covers journal and patent publications from 2003 to March 2006.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397173     DOI: 10.2174/156802608783955737

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  4 in total

1.  Design and x-ray crystal structures of high-potency nonsteroidal glucocorticoid agonists exploiting a novel binding site on the receptor.

Authors:  Keith Biggadike; Randy K Bledsoe; Diane M Coe; Tony W J Cooper; David House; Marie A Iannone; Simon J F Macdonald; Kevin P Madauss; Iain M McLay; Tracy J Shipley; Simon J Taylor; Thuy B Tran; Iain J Uings; Victoria Weller; Shawn P Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-12       Impact factor: 11.205

2.  Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.

Authors:  Thomas Stock; Dona Fleishaker; Xin Wang; Arnab Mukherjee; Charles Mebus
Journal:  Int J Rheum Dis       Date:  2017-03-22       Impact factor: 2.454

3.  Population Pharmacokinetics of Fosdagrocorat (PF-04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis.

Authors:  Barry Weatherley; Lynn McFadyen; Brinda Tammara
Journal:  Clin Transl Sci       Date:  2017-11-04       Impact factor: 4.689

4.  In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor.

Authors:  Sharon L Ripp; Arnab Mukherjee; Heather Eng; Thomas Stock; Dona Fleishaker; Tina Checchio; Brinda Tammara
Journal:  Clin Pharmacol Drug Dev       Date:  2017-11-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.